therap: lupsma versus cabazitaxel for prostate cancer
Published 3 years ago • 199 plays • Length 2:56Download video MP4
Download video MP3
Similar videos
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
3:41
177lu-psma-617 vs. cabazitaxel for mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
4:08
lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
-
1:37
cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
-
5:59
lupsma vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docet...
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
2:46
upfrontpsma trial: 177lu-psma-617 and docetaxel in mhnpc
-
2:06
mcrpc: cabazitaxel re-challenge
-
5:51
lupsma vs cabazitaxel for metastatic castration-resistant prostate cancer
-
10:47
therap trial
-
4:00
therap trial and effectiveness of lu-psma-617
-
7:09
cabazitaxel use in metastatic prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
6:59
first results of therap trial
-
3:16
updated therap data further support lupsma for mcrpc | michael hofman
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer